Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial

What is it about?

What is it about? Up to two in five people who have type 1 diabetes also have long-term or ‘chronic’ kidney disease (CKD). In a clinical trial, the drug finerenone was shown to reduce kidney damage in people with type 1 diabetes and CKD. Higher blood sugar levels and long-standing diabetes are associated with increased kidney risk. Therefore, we tested whether the effects of finerenone on the kidneys were consistent across patients with different blood sugar levels and duration of type 1 diabetes. Why is it important? This study found that finerenone reduced kidney damage regardless of blood sugar levels and diabetes duration. These results suggest that finerenone may help reduce kidney damage in a broad range of patients with type 1 diabetes and CKD.

Featured Image